Cardiovascular outcomes with p2y12 inhibitors after coronary artery bypass graft surgery

Patients who undergo coronary artery bypass graft (CABG) surgery remain at high risk for major adverse cardiovascular events (MACE) despite contemporary pharmacotherapy. Although commonly used, there is uncertainty whether P2Y12 inhibitors reduce MACE in these patients. This study aimed to evaluate the effects of P2Y12 inhibitors on MACE in patients who underwent CABG surgery.